Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Activity Overview

Although antibody-drug conjugates (ADCs) can offer substantial survival benefits, their distinct mechanisms of action can also result in serious ocular complications for patients. These events — paired with the rapid integration of these therapies into clinical care — represent a pressing challenge in real-world practice. In this program, a multidisciplinary panel of expert faculty discusses opportunities for improved prevention, monitoring, and management of ocular toxicities with specific ADCs.

This educational activity is an archive of the live presentation held on October 11, 2026.

Target Audience

This educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in the management of patients receiving antibody-drug conjugates and other targeted anticancer therapies associated with ocular toxicity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the underlying biological and pharmacologic mechanisms contributing to ocular adverse events associated with antibody-drug conjugates (ADCs) across diverse oncologic indications
• Apply evidence-informed approaches to the prevention, surveillance, and management of ADC-related ocular toxicities within routine clinical care
• Implement structured integration of ophthalmic evaluations into multidisciplinary oncology practice using standardized grading systems, clear documentation, and coordinated interprofessional communication
• Develop patient-centered communication strategies that support shared decision-making

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.